DickSIM
Prima o poi....ci becco!
The 5th Annual Ophthalmic Drug Development and Delivery Summit
Emerging Scientific Innovations in Treating Ocular Diseases: Targets, Delivery and Regulatory Strategies
September 21st - 22nd, 2009
Hilton San Diego/Del Mar
Now in its fifth year, PEA’s Ophthalmic Drug Development and Delivery Summit will enlighten you about the latest developments regarding disease pathogenesis and novel targets for treatment of ocular diseases such as:
Retinopathies
Wet and dry AMD
Retinitis pigmentosa
DME/DR
Glaucoma
Ocular surface diseases
Inflammatory diseases of the eye
In addition to that, the summit also features a couple of sessions addressing the latest developments in the following areas:
Ocular Drug Delivery
Current expectations of regulatory agencies
Latest developments regarding animal models
We’d like to thank our expert speaking faculty:
Kay Rittenhouse, Ph.D., Pfizer Inc.
Rajendra Apte, MD, Ph.D., Washington University School of Medicine
Michael Swit, The Weinberg Group Inc.
David Eveleth, Ph.D., Pfizer Inc.
Remis Bistras, Ph.D., Eye Gate Pharmaceuticals
Joachim Kohn, Ph.D., Rutgers University
Gerard Lutty, Ph.D., Wilmer Ophthalmological Institute
P. Vasanth Rao, Ph.D., Duke University School of Medicine
Barbara Wirostko, MD, Pfizer Inc.
Devin Welty, Ph.D., Allergan Inc.
Paul Ashton, Psivida Ltd.
Ashim Mitra, Ph.D., University of Missouri
Gary Novack, Ph.D., Pharma-Logic Development, Inc.
Konrad Kauper, Neurotech Pharmaceuticals
Emerging Scientific Innovations in Treating Ocular Diseases: Targets, Delivery and Regulatory Strategies
September 21st - 22nd, 2009
Hilton San Diego/Del Mar
Now in its fifth year, PEA’s Ophthalmic Drug Development and Delivery Summit will enlighten you about the latest developments regarding disease pathogenesis and novel targets for treatment of ocular diseases such as:
Retinopathies
Wet and dry AMD
Retinitis pigmentosa
DME/DR
Glaucoma
Ocular surface diseases
Inflammatory diseases of the eye
In addition to that, the summit also features a couple of sessions addressing the latest developments in the following areas:
Ocular Drug Delivery
Current expectations of regulatory agencies
Latest developments regarding animal models
We’d like to thank our expert speaking faculty:
Kay Rittenhouse, Ph.D., Pfizer Inc.
Rajendra Apte, MD, Ph.D., Washington University School of Medicine
Michael Swit, The Weinberg Group Inc.
David Eveleth, Ph.D., Pfizer Inc.
Remis Bistras, Ph.D., Eye Gate Pharmaceuticals
Joachim Kohn, Ph.D., Rutgers University
Gerard Lutty, Ph.D., Wilmer Ophthalmological Institute
P. Vasanth Rao, Ph.D., Duke University School of Medicine
Barbara Wirostko, MD, Pfizer Inc.
Devin Welty, Ph.D., Allergan Inc.
Paul Ashton, Psivida Ltd.
Ashim Mitra, Ph.D., University of Missouri
Gary Novack, Ph.D., Pharma-Logic Development, Inc.
Konrad Kauper, Neurotech Pharmaceuticals